<DOC>
	<DOC>NCT00233506</DOC>
	<brief_summary>- CpG has the potential to stimulate the immune system - this study will evaluate the safety of CpG given sub-q or IV - purpose is to measure biological changes in CLL cells after receiving CpG</brief_summary>
	<brief_title>A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Diagnosis of CLL CLL previously treated Hemoglobin &gt;/= 10 Platelets &gt;/= 50,000 Neutrophils &gt;= 1,000 patients with brain mets patients with autoimmune disease patients on corticosteroids or immunosuppressants patients with uncontrolled intercurrent illness pregnant women HIV patients receiving combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CpG 7909</keyword>
	<keyword>CLL</keyword>
</DOC>